Akoya Biosciences Statistics
Share Statistics
Akoya Biosciences has 49.56M shares outstanding. The number of shares has increased by 1.14% in one year.
Shares Outstanding | 49.56M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.23% |
Owned by Institutions (%) | n/a |
Shares Floating | 20.01M |
Failed to Deliver (FTD) Shares | 3.13K |
FTD / Avg. Volume | 1.35% |
Short Selling Information
The latest short interest is 1.60M, so 3.23% of the outstanding shares have been sold short.
Short Interest | 1.60M |
Short % of Shares Out | 3.23% |
Short % of Float | 7.8% |
Short Ratio (days to cover) | 13.43 |
Valuation Ratios
The PE ratio is -3.42 and the forward PE ratio is -5.8.
PE Ratio | -3.42 |
Forward PE | -5.8 |
PS Ratio | 2.24 |
Forward PS | 1 |
PB Ratio | 4.03 |
P/FCF Ratio | -3.97 |
PEG Ratio | n/a |
Enterprise Valuation
Akoya Biosciences Inc. has an Enterprise Value (EV) of 219.42M.
EV / Earnings | -3.47 |
EV / Sales | 2.27 |
EV / EBITDA | -4.81 |
EV / EBIT | -3.8 |
EV / FCF | -4.02 |
Financial Position
The company has a current ratio of 3.45, with a Debt / Equity ratio of 1.46.
Current Ratio | 3.45 |
Quick Ratio | 2.94 |
Debt / Equity | 1.46 |
Total Debt / Capitalization | 59.41 |
Cash Flow / Debt | -0.65 |
Interest Coverage | -6.58 |
Financial Efficiency
Return on equity (ROE) is -1.18% and return on capital (ROIC) is -41.37%.
Return on Equity (ROE) | -1.18% |
Return on Assets (ROA) | -0.35% |
Return on Capital (ROIC) | -41.37% |
Revenue Per Employee | 292.83K |
Profits Per Employee | -191.89K |
Employee Count | 330 |
Asset Turnover | 0.54 |
Inventory Turnover | 2.26 |
Taxes
Income Tax | 40.00K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -48.87% in the last 52 weeks. The beta is 1.35, so Akoya Biosciences 's price volatility has been higher than the market average.
Beta | 1.35 |
52-Week Price Change | -48.87% |
50-Day Moving Average | 2.7 |
200-Day Moving Average | 3.02 |
Relative Strength Index (RSI) | 50.14 |
Average Volume (20 Days) | 232.01K |
Income Statement
In the last 12 months, Akoya Biosciences had revenue of $96.63M and earned -$63.32M in profits. Earnings per share was $-1.43.
Revenue | 96.63M |
Gross Profit | 56.30M |
Operating Income | -57.67M |
Net Income | -63.32M |
EBITDA | -45.63M |
EBIT | -57.67M |
Earnings Per Share (EPS) | -1.43 |
Balance Sheet
The company has $83.13M in cash and $85.71M in debt, giving a net cash position of -$2.58M.
Cash & Cash Equivalents | 83.13M |
Total Debt | 85.71M |
Net Cash | -2.58M |
Retained Earnings | -230.07M |
Total Assets | 129.97M |
Working Capital | 48.87M |
Cash Flow
In the last 12 months, operating cash flow was -$50.90M and capital expenditures -$3.65M, giving a free cash flow of -$54.55M.
Operating Cash Flow | -50.90M |
Capital Expenditures | -3.65M |
Free Cash Flow | -54.55M |
FCF Per Share | -1.23 |
Margins
Gross margin is 58.27%, with operating and profit margins of -59.68% and -65.53%.
Gross Margin | 58.27% |
Operating Margin | -59.68% |
Pretax Margin | -65.49% |
Profit Margin | -65.53% |
EBITDA Margin | -47.22% |
EBIT Margin | -59.68% |
FCF Margin | -56.45% |
Dividends & Yields
AKYA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -63% |
FCF Yield | -48.38% |
Analyst Forecast
The average price target for AKYA is $3.5, which is 54.2% higher than the current price. The consensus rating is "Hold".
Price Target | $3.5 |
Price Target Difference | 54.2% |
Analyst Consensus | Hold |
Analyst Count | 8 |
Scores
Altman Z-Score | -2.46 |
Piotroski F-Score | 3 |